The firm will discontinue its SensiGene Fetal RHD test.
The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.
The articles focus on test regulation and clinical validation, both in the context of breast cancer risk and general variant assessment.
With more than 100 tumor samples from 92 women with ovarian cancer, researchers searched for mutations related to treatment resistance and relapse.
Editas will earn an upfront payment of $25 million to launch three research programs to apply CRISPR/Cas9 and TALEN genome editing to Juno's immunotherapies.
In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.
Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.
A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.
The White House says ethical discussions about genome editing of the human germline are needed.